Documents

FINAL ASSESSMENT  OF THE COST ACTION 17112

CA17112 Final Assessment Review (16/10/2018 to 15/04/2023)

ANNOTATED RULES -GP5 

The present version of the Annotated Rules for COST Actions (COST 094/21; V1.3) shall enter into force on 1st November 2022.

The Annotated Rules shall cancel and replace:
• The Guidelines for COST Action Management, Monitoring and Final Assessment;
• The Guidelines for the communication, dissemination and exploitation of COST Action results and outcomes;
• The COST Vademecum;
• The Derogation Procedure.

 

Prof. Mª Isabel Lucena, scientific coordinator of the COST Action CA-17112 gave a talk at the University of Malaga last 21st February 2023 about Drugs hepatotoxicity. See it here.

Launch of Personalised Prescribing report

Prof Guruprasad Aithal, Vice Chair of the COST Action CA17112 who presented evidence to the working party said- ‘There are inter-individual variations in the way medicines work. Considering one’s genetic make-up assists while prescribing, increasing the benefits and reducing the adverse effect of the medications. We know of genetic variations which effect over 40 medicines. We are calling for Health Services to offer genetic tests to improve safe and effective prescribing’.

Press Release

Report

GUIDELINES FOR COST ACTIONS

Co-branding rules are important in order to acknowledge COST as the funding source.

NEWSLETTERS

 


2nd TRAINING COURSE, COST ACTION 17-112: RECENT ADVANCES ON STEM CELL RESEARCH AND CELL THERAPIES.

Lisbon, Portugal. 10th-11th October 2019

 

1st TRAINING COURSE, COST ACTION 17-112: ASSESSMENT OF DRUG-INDUCED LIVER INJURY: KEY RULES AND COMMON PITFALLS. HOW TO MAKE A CLINICAL NARRATIVE.

Recognition by EUROTOX as a Continuing professional development (CPD) course of 11 teaching hours.

Presentations

DILI CASES

Miren Garcia-Cortes, Camilla Stephens, Aida Ortega-Alonso, Mercedes Robles-Diaz, Judith Sanabria (Spain)

Grant beneficiaries & survey assessment

Short-Term Scientific Missions (STSMs). COST ACTION 17-112

  • E-COST-GRANT-CA17112-68ac2a76

*Participant: Dr Nebojša Stilinović. University of Novi Sad, Faculty of Medicine Novi Sad (Novi Sad, Serbia)

*Type of Mission: Clinical

*Location: University of Ljubljana, Faculty of Medicine. Ljubljana (Slovénie)

*Responsible: Prof. Irina Milisav Ribarič.

Email: irina.milisav-ribaric@zf.uni-lj.si

*Dates: 2023-02-13 – 2023-03-06

 

  • E-COST-GRANT-CA17112-a30dc9af

*Participant: Miguel Zoubek, Prospective European Drug-induced Liver Injury Registry (Malaga, Spain)

*Type of Mission: Clinical

*Location: Department of Dermatology and Venerology, Medical Center of the University of Freiburg; German Center for Documentation of Severe Skin Reactions (Freiburg, Germany)

*Responsible: Prof. Dr. Dr. K. Eyerich / Mrs. S. Acker-Heinig. Email: sabine.acker-heinig@uniklinik-freiburg.de

*Dates: 2022-11-20 – 2022-12-17

 

  • E-COST-GRANT-CA17112-96495b0b

*Participant: Ana Serras, Faculdade de Farmácia da Universidade de Lisboa (Lisbon, Portugal)

*Type of Mission: Clinical

*Location: Biomedical Research Institute of Malaga (IBIMA), Universidad de Málaga

*Responsible: Prof. Mª Isabel Lucena. Email: lucena@uma.es

*Dates: 2022-09-26 – 2022-10-28

 

  • E-COST-GRANT-CA17112-c24353ac

*Participant: Ana Serras, Faculdade de Farmácia da Universidade de Lisboa (Lisbon, Portugal)

*Type of Mission: Clinical

*Location: Biomedical Research Institute of Malaga (IBIMA), Universidad de Málaga

*Responsible: Prof. Mª Isabel Lucena. Email: lucena@uma.es

*Dates: 2022-08-29 – 2022-09-16

 

  • E-COST-GRANT-CA17112-fc91b1db

*Participant: Camilla Stephens, Malaga University (Malaga, Spain)

*Type of Mission: Clinical

*Location: Nottingham University, (Nottingham, UK)

*Responsible: Guru Aithal. Email: Guru.Aithal@nottingham.ac.uk

*Dates: 2022-09-19 – 2022-09-30

 

  • E-COST-GRANT-CA17112-966a467a

*Participant: Laura Moran, Universidad Complutense de Madrid (Madrid, Spain)

*Type of Mission: Clinical

*Location: Institute of Physics of the Czech Academy of Sciences (Prague, CZ)

*Responsible: Dr Oleg Lunov. Email: lunov@fzu.cz

*Dates: 2022-07-04 – 2022-09-30

 

  • E-COST-GRANT-CA17112-24c11ac9.

*Participant: Olga Estévez Vázquez. Complutense University Madrid (Madrid, Spain)

*Type of Mission: Clinical

*Location: Bilkent University, Ankara (Turkey)

*Responsible: Dr Özlen Konu. Email: konu@fen.bilkent.edu.tr

*Dates: 2022-04-29 – 2022-07-24

 

  • ECOST-STSM-Request-CA17112-48808. In vitro isolation of keratinocytes and fibroblasts from punch biopsy.

*Participant: Antonio Segovia Zafra, University of Málaga (Spain)

*Type of Mission: Clinical

*Location: National Reference Center for Rare Skin Diseases (Université
de Bordeaux), Bordeaux (France)

*Responsible: Dr Muriel Cario-André. Email: muriel.cario-andre@u-bordeaux.fr

*Dates: 2021-10-11 – 2021-10-24

 

  • ECOST-STSM-Request-CA17112-48461. Establishment of iPSC differentiated to human hepatocyte knockouts.

*Participant: Alejandro Hionides. Universidad Complutense de Madrid (Madrid, Spain)

*Type of Mission: Clinical

*Location: University of Oslo, Sognsvannsveien 9, 0372 Oslo (Norway)

*Responsible: Dr Gareth John Sullivan. Email: g.j.sullivan@medisin.uio.no

*Dates: 2021-09-01 – 2021-10-31

 

  • ECOST-STSM-Request-CA17112-48249. Advancing in vitro models of DILI: key techniques for the study of hepatotoxicity in cell cultures

*Participant: Daniel Enrique Di Zeo Sánchez. Biomedical Research Institute of Málaga (IBIMA) / University of Málaga (Málaga, Spain).

*Type of Mission: Clinical

*Location: Faculty of Pharmacy of the University of Lisbon

*Responsible: Joana Miranda. Email: jmiranda@ff.ul.pt 

*Dates: 2021-07-01- 2021-07-31

  • ECOST-STSM-Request-CA17112-48256

*Dates: 2021-09-01 – 2021-10-31

  • ECOST-STSM-Request-CA17112-47460. DILI principles in detection, characterization, phenotyping, risk assessment and adjudication. Management of DILI databases. Pathophysiology, therapeutic strategies and new biomarkers in DILI using patient-derived dermal fibroblasts, keratinocytes and hep

*Participant: Lauryna Aukštikalnė. Lithuanian University of Health Sciences Institute of Physiology and Pharmacology (Kaunas)

*Type of Mission: Clinical

*Location: Universidad de Málaga (UMA), Málaga, Spain

*Responsible: Dr. María Isabel Lucena, lucena@uma.es

*Dates: 2021-01-11 – 2021-02-28

 

  • ECOST-STSM-Request-CA17112-46009. Training in the use of HepaRGs and monitoring POR expression.

*Participant: Francisco Esteves. Faculdade de Ciências Médicas, UNL, Lisboa (Portugal).

*Type of Mission: Basic

*Location: Institute of Bioengineering, University of Edinburgh, Scotland (UK)

*Responsible: Dr. Leonard J. Nelson

*Dates: 01.03.2020-15.03.2020

  • ECOST-STSM-Request-CA17112-46089. Methodology of systematic review of observational studies in DILI

*Participant: Cristiana Torres Freixo, Faculdade de Medicina. Universidade do Porto. Porto (Portugal)

*Type of Mission: Clinical

*Location: Nottingham Digestive Diseases Centre, Nottingham (UK)

*Responsible: Dr. Guruprasad Aithal

*Dates: 19.01.2020-05.02.2020

 

  • ECOST-STSM-Request-CA17112-45167. ROLE OF NRF2 IN APAP-MEDIATED TOXICITY

*Participant: Nuria López-Alcántara (Spain)

*Type of Mission: Basic

*Location: Institute of Physics of the Czech Academy of Sciences, Prague (Czech Republic)

*Responsible: Dr. Oleg Lunov

*Dates: 02.12.2019-22.12.2019

 

  • ECOST-STSM-Request-CA17112-45133. VIRAL AND AUTOIMMUNE HEPATITIS, CIRRHOSIS, ACUTE LIVER FAILURE, DILI, HILI INTRAHEPATIC CHOLESTASIS OF PREGNANCY

*Participant: Goran Bokan Faculty of medicine, Banja Luka, BA

*Type of Mission: Clinical

*Location: Internal Medicine & Hepatology, DIBIMIS, University of Palermo (Italy)

*Responsible: Dr. Anna Licata

*Dates: 30.09.2019-31.10.2019

 

  • ECOST-STSM-Request-CA17112-45122. “SHORT TERM SCIENTIFIC MISSION” FOR THE LIVER FIBROSIS DIAGNOSIS THROUGH THE LIVER ELASTROGRAPHY. 

*Participant: Enrique del Campo, UMA. Málaga (Spain)

*Type of Mission: Clinical

*Location: Internal Medicine & Hepatology, DIBIMIS, University of Palermo (Italy)

*Responsible: Dr. Anna Licata

*Dates: 10.07.2019-18.10.2019

 

CA-17112. PROSPECTIVE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK

CLOSING MEETING. 6th Management Committee & 8th Core Group Meetings.

9-10 March 2023. Prague, Czechia.

 

CA-17112. WORKSHOP OMICS STUDIES IN DILI ALONG WITH A SESSION ON DILI IN PAEDIATRICS. WORKING GROUPS/ 7th CORE GROUP/ 5th MANAGEMENT COMMITTEE MEETINGS.

09-11 September 2022. Istanbul, Turkey

 

 

BIOMARKERS & REGULATORY SCIENCE IN DILI
EARLY CAREER INVESTIGATORS FORUM. 6th CORE GROUP MEETING.

17-19 MARCH 2022. KAUNAS, LITHUANIA.

 

 

 

 

WORKING GROUPS/ 5th CORE GROUP/ 4th MANAGEMENT COMMITTEE MEETINGS / 3rd TRAINING SCHOOL. 11-13 OCTOBER 2021. NOTTINGHAM, UK

 

 

 

 

4th Core Group Meeting. COST Action 17112 PRO-EURO DILI NET. 26th November 2020. 2.00-3.00 PM (GMT)

 

 

 

 

CA-17112 Management Committee updates & Working Groups meeting @ EASL Digital International Liver Congress 2020

 

 

Lectures. 29th August 2020.

Core Group Meetings (CGM)

AGENDA 1st CGM (Draft)

Lisbon, 9/01/2019


Management Committee Meetings (MCM)

2nd MC Meeting Agenda Malaga 2019

Málaga, 14-15/03/2019

AGENDA  1st MCM Kick Off

Brussels, 16/10/2018

Minutes  1st MCM

Brussels, 16/10/2018

Final Andrade  1st MCM

Brussels, 16/10/2018

Annex1 Fact-sheet 1st MCM

Brussels, 16/10/2018

Annex3 attendance list 1st MCM

Brussels, 16/10/2018

Cost Press release

Málaga 19.12.18


Working Group Meetings (WGM)

Plenary lectures. 2 WGs Meeting. Palermo, 10th October 2019

Reports from WGs Leaders: where do we stand now? 2 WGs Meeting. Palermo, 10th October 2019

Short presentations from WGs Leaders. 1 WGs Meeting. Málaga, 14 March 2019

Plenary lectures. 1 WGs Meeting. Málaga, 14 March 2019

The Management Committee has approved the ITC conference grants awarded to the PhD Students, Ms. Joana Rodrigues and Ana Serras (Portugal) with the purpose of her attendance for the ITC 2022 – XVIth International Congress of Toxicology to be held in Maastricht, the Netherlands, from September 18 to 21, 2022.

They will both deliver a talk entitled: “Uniting in Toxicology”

The Management Committee has approved the ITC conference grant awarded to the PhD Student, Ms. Joana Saraiva (Portugal) with the purpose of her attendance for the EUROTOX congress 2019  hold in Helsinki (8-11 September).

Her abstract entitled: “Hepatocyte-like cells in microfluidic devices: a new platform for disease modelling, drug screening and toxicology”
(Abstract ID: 250), submitted as “Poster” has been accepted and selected one of the 5 top posters presentation. She has adquired new concepts in pre-clinical methods in DILI that undoubtedly will help her to successfully continue her research on the field of DILI.

In order to support young investigator ́s career development and to encourage interactions among the participants in the COST Action 17112, we are launching a New Insights: Young Investigators Seminar Series. We propose this as a series of talks, ONCE monthly, given by early career investigators (ECIs) – with the supervision of their tutors (both hosts and mentors). The outline of the session would be a brief introduction of the speaker by the mentor, a talk around 45 min with 15 min left for discussion. Conferences will be held the 3rd Wednesday of each month at 16.30h (CET) starting from June 17.

Lily Dara is an NIH-funded physician-scientist at the University of Southern California with a research interest in Drug-Induced Liver Injury and Autoimmune Liver Diseases including autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). She is a graduate of Shahid Beheshti University of Medical Sciences in Tehran, Iran. She completed residency and Chief residency at Griffin Hospital in CT, a Yale affiliated program. She became interested in liver disease during her residency while rotating on the Yale Liver Service, which led her to the laboratory of Dr. Neil Kaplowitz during fellowship. In the Kaplowitz lab she studied the mechanisms of hepatocyte cell death during acetaminophen- induced acute liver injury with a focus on necrosis, apoptosis, and necroptosis signaling. She is a tenure track Assistant Professor of Medicine and currently studies cell death subroutines in various forms of hepatotoxicity and immune-mediated liver injury such as immune checkpoint inhibitors (ICIs) using basic mouse models and translational approaches. Her clinical research is focused on drug-induced hepatotoxicity, AIH, PBC, and their variant syndromes. She reviews manuscripts for multiple journals and serves on the editorial board of Gastroenterology, is the Vice Chair of the AASLD Hepatotoxicity SIG, and is a member of the study section of the AASLD foundation, the Research Awards Committee..

See the video here

Guest: Lili Dara, University of Southern California, USA

Date: 12th April 2023. 17.00h (CEST)

Dr. Arie Regev is a gastroenterologist and hepatologist. He is Vice President of Medical Global Patient Safety at Eli Lilly and Company. He heads Eli Lilly’s Safety Advisory Hub and is the chair of Eli Lilly’s Liver Safety Advisory Committee. Dr. Regev is an associate professor of medicine at the division of gastroenterology and hepatology of Indiana University School of Medicine. He is a co-chair of the Council of International Organizations of Medical Sciences (CIOMS) working group on Drug Induced Liver Injury (DILI). He is the founding co-chair of the IQ-DILI initiative. Prior to joining Eli Lilly, he was an associate professor of medicine and director of the hepatology training program of the University of Miami School of Medicine.

See the video here

Guest: Arie Regev, MD, FAASLD

Date: 27th March 2023. 16.30h (CEST)

Dr. Paul Watkins is the Howard Q Ferguson Distinguished Professor of Medicine, Pharmacy and Public Health, and director of the Institute for Drug Safety Sciences at the University of North Carolina, Chapel Hill. He is a clinically trained hepatologist with long standing interest Drug-Induced Liver Injury (DILI). He serves as co-chair of the Steering and Executive Committees, and Chair of the Genetics Committee, for the U.S. Drug-Induced Liver Injury Network funded by the NIH. He founded, and now serves as chair of the Scientific Advisory Board for a public-private partnership (the DILI-sim Initiative) that is applying quantitative systems toxicology to understand and predict liver safety liabilities in new drug candidates. Dr. Watkins is one of the most highly cited authors in the field of pharmacology (ISIhighlycited.com). He is the recipient of numerous honors and awards including an NIH MERIT Award, the Rawls-Palmer Award for Progress in Medicine from the American Society for Clinical Pharmacology and Therapeutics, the Agilent Thought Leader Award, and the Career Award from the Toxicology Section of the American Society of Pharmacology and Experimental Therapeutics.

See the video here

Guest: Dr Paul Watkins

Date: 22nd February 2023. 16.30h (CET)

Dr. Trivedi is a Clinician Scientist in the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), based at the University of Birmingham. Dr. Trivedi is a Consultant Hepatologist who has devoted his clinical and research career to studying immune-mediated and chronic cholestatic liver disease, specifically primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).

Palak is chief investigator for the UK-PSC consortium, and was elected chair of the British Association for Study of the Liver Special Interest Group (BASL SIG) for immune-mediated liver disease in 2018.

See the video here

Guest: Dr. Palak Trivedi

Date: 18th January 2023. 16.30h (CET)

Laura Morán Blanco, is a PhD student in the laboratory of Dr. Francisco Javier Cubero in the department of Immunology, Ophthalmology and ORL in school of Medicine of the Complutense University of Madrid. She was born in Gijón, Asturias, and studied Biology degree in the university of Oviedo. After that, she has moved to Madrid to study a master’s degree in Immunology in the Complutense University of Madrid, where she is developing her PhD

During her talk, she explained the project in which she has been involved during the STSM in Prague, working in the laboratory supervised by Dr. Oleg Lunov in the Institute of Physics in Prague, Czech Republic. Her research has been focused on the role of redox signaling during drug induced-liver injury (DILI) through the use of an immortalized human cell line transfected with siKeap1.

See the video here

Guest: Laura Morán Blanco

Date: 14th December 2022. 16.30h (CET)

Our last speaker, Barbora Smolkova is Post-doctoral Researcher at The Institute of Physics in Prague, currently working in the Laboratory of Biophysics of Oleg Lunov. She was born in Slovakia and finished her Master degree in Molecular biology in Bratislava. After that she moved to Prague where she finished her Ph.D. in Oleg Lunov’s laboratory in May 2022. After graduation, Barbora moved to Oslo and joined the group of Gareth J. Sullivan at The Department of Pediatric Research of Oslo University Hospital for 7 months.

In her talk she will describe her work on the project during my scientific mobility internship in Oslo where she analysed the mitochondrial dynamics and function in iPSC-derived liver organoids. In recent years, organoids have shown great potential in many areas of fundamental and applied research such as models for studying development and disease and when combined with the use of patient- derived iPSC allow us to model specific disorders and potential treatments.

See the video here

Guest:Barbora Smolkova (Prague, Czechia)

Date: 17th November 2022. 16.00h (CET)

 

Olga Estévez Vázquez, is a PhD student in the laboratory of Dra. Yulia A. Nevzorova in the department of Immunology of the Complutense University of Madrid. She was born in Vigo, Pontevedra, and studied her Biology degree in the University of Santiago de Compostela. After it, she has moved to Madrid to study a master degree in Biomedicine in the Complutense University of Madrid, were she is actually developing her PhD. Before joining Yulia’s group, she was doing an Erasmus + staying in the Pasteur Institute of Paris.
During her talk, she is going to explain the project in which she has been involved during her STSM in Turkey, working in the laboratories of Prof. Özlen Konü, at Bilkent University in Ankara and Dra. Gülçin Çakan in the Izmir Biomedicine and Genome Center (IBG) located in Izmir, Turkey. Her research has been focused on the development of a preclinical DUAL animal model (alcohol-associated liver disease plus metabolic-associated fatty liver disease) in zebrafish, and moreover its combination with acetaminophen (APAP).
This study will not only significantly increase our knowledge on the mechanisms of MAFLD-alcohol-DILI communication, but will also reveal possible future interventional strategies and significantly improving care of MAFLD patients.

See the video here

Guest: Olga Estévez Vázquez

Date: 19th October 2022. 16.30h (CEST)

Our last speaker was  Dr. Sabine Weber, Department of Medicine II, LMU Klinikum, Munich (Germany)

See the video here

Guest: Dr. Sabine Weber

Date: 21st September 2022. 16.30h (CEST)

Our last speaker was  Dr. Jorge Simón Espinosa, CIC bioGUNE , Metabolomics Unit, CIBERehd-ISCIII.

See the video here

Guest: Dr. Jorge Simón Espinosa

Date: 15th June 2022. 16.30h (CEST)

Our speaker was Dr. Oleg Lunov, Ph.D.  , he has completed a PhD in Molecular Medicine Ulm, Germany in 2011. After, he worked as post-doctoral researcher in the Institute of Pharmacology, Ulm University, Germany. In 2014 Dr. Lunov received Purkyně fellowship and joined Institute of Physics of the Czech Academy of Sciences, Prague. From 2016 Dr. Lunov is Head of the Laboratory of Biophysics at Institute of Physics of the Czech Academy of Sciences, Prague.

You can get more information in this web

See the video here Potential of nanoparticles as livery injury agents

Guest: Dr. Oleg Lunov, Ph.D.

Date: 18th May 2022. 16.30h (CEST)

Our speaker was Daniel Di Zeo Sánchez, although now based in Malaga, Daniel’s family background comes from a long history of international mobility across 5 different countries. He graduated in Biochemistry with a mention in Molecular and Applied Biochemistry by the University of Malaga (UMA) and University of Seville (2013-2017) and holds a master’s in Advanced Biotechnology (UMA, 2018-2019). After finishing his superior studies, he benefited from long-term grants and contracts such as a 6-months grant for studying molecular biology of cancer, and an 18-month contract in the field of microbiology.

His most recent professional experience came at the end of 2019 when, moved for the curiosity of solving human health problems, he joined the Hepatogastroenterology, Pharmacology and Translational Clinical Therapeutics group at the Biomedical Research Institute of Malaga (IBIMA). Since then, he enrolled in the PhD programme of Biomedicine, Translational Research and New Health Technologies (UMA) to pursue his thesis project, focused on studying mechanistic and immunological features of the disease known as drug-induced liver injury, in continuous interaction with clinicians and the pharmaceutical industry.

Daniel di Zeo Sánchez will present his experience during a 3-month Short Term Scientific Mission in the laboratory of Prof. Joana P. Miranda, at the Faculty of Pharmacy of the University of Lisbon. During this period, he worked on in vitro techniques for the study of immunological mechanisms of drugs related to idiosyncratic hepatotoxicity, using different sources of liver and immune cells as models.

See the video here 

Advancing in vitro models of DILI: key techniques for the study of the inmunological features of idiosyncratic hepatotoxicity in cell cultures

Guest: Daniel Di Zeo Sánchez.

 

Our speaker was be Prof. Dr. Jan G. Hengstler. Dr. Hengstler has completed a PhD in Medical and health sciences with a specialty of DNA damage at the University of MainzI. From 2007 Dr Hengstler is Professor (W3) and Scientific Director at the Leibniz Research Centre for Working Environment and Human Factors in Dortmund.

See the video here:

Functional imaging of hepatotoxicity: Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity

Date: 16th March 2022, at 16.30h (CET)

Guest: Prof. Dr. Jan G. Hengstler.

 

Our speaker was  Pamela Bachour El Azzi, professor at the Lebanese University, Université Saint Joseph and Université Antonine for 7 years. She is commercial director and scientific consultant at Wepredic.

Dr. Bachour El Azzi has completed a PhD in Biology and health sciences with a specialty of toxicology at the Université de Rennes I and the Lebanese University. The main PhD work of Dr. Bachour El Azzi was the characterization of bile acid transporters in HepaRG cells and the investigation of drug-induced cholestatic mechanisms. She studied cellular mechanisms underlying chlorpromazine-induced intrahepatic cholestasis in vitro in the presence or not of an inflammatory context.

Drug-induced cholestasis: models, biomarkers and industrial challenges.

Date: 16th February 2022, at 16.30h (CET)

Guest: Pamela Bachour El Azzi

 

Our speaker was Ivan Capo from the University Clinical Centre of Vojvodina.

Role of histopathology in the assessment of animal models in DILI prediction.

Date: 21st January, at 16.30h (CET)

Guest: Ivan Capo

 

Our last speaker was Alejandro Hionides from the Oslo Universitetssykehus.

Generation of cell and gene iPSCs specific knockouts.

Date: 15th December, at 16.30h (CET)

Guest: Alejandro Hionides

 

Our last speaker was Lauryna Aukštikalnė, MD from the Lithuanian University of Health Sciences Hospital Kaunas Clinics.

Building bridges between Kaunas and Malaga in the middle of the pandemic: a short term scientific mission.

Date: 20th October, at 16.30h (CEST)

Guest: Lauryna Aukštikalnė

 

Our next speaker was Goran Bokan, MD from the UCC RS of Banja Luka.

See the video here: Future perspectives in DILI-nisation: How to save the liver?

Date: 16th September, at 16.30h (CEST)

Guest: Goran Bokan

 

Our next speakers was Ismael Alvarez and Hao Niu from the Departments of Medicine and Pharmacology at Malaga University, IBIMA, who will be addressing an important topic on translational research in DILI

Clinical Trials and Drug-Induced Liver Injury: what have we learnt and where can we go.

As members of the working group on: Design and Endpoints in Clinical DILI Investigations and Trials, they have led a systematic review with meta-analysis on the treatment and prevention of DILI which may pave the way to set up an international multicentre research network to investigate the effectiveness of known and novel interventions that could improve clinical outcomes of DILI.

Date: 15th JULY, at 16.30h (CEST)

Guests: Ismael Alvarez, Hao Niu

 

 

Our first guest will be Nuria López-Alcántara who left Javier Cubero´s lab to enjoy a short term scientific-mission (STSM) in the laboratory of Oleg Lunov at the Institute of Physics in Prague (Czech Republic). She will narrate her experience and learning, will discuss the methods/ techniques used and what she aims to develop further in the future.

Date: 17th JUNE, at 16.30h (CET)

Guest: Nuria López-Alcántara

 

  • Antonio Segovia Zafra from the University of Malaga (Spain) has been awarded a VM grant for 1500 € (11 Jan.-31 Mar. 2023) (E-COST-GRANT-CA17112-2b6b27a3)
  • Hao Niu from the University of Malaga (Spain) has been awarded a VM grant for 1500 € (20 Dec. 2022-01 Mar. 2023). Title: Effect of corticosteroids in the outcome of drug-induced liver injury: a propensity scores analysis (E-COST-GRANT-CA17112-51ec79d9)
  • Marina Villanueva Paz from the University of Malaga (Spain) has been awarded a VM grant for 1500 € (15 Nov.2022-15 Mar 2023) (E-COST-GRANT-CA17112-f7b17bc4)
  • Ismael Álvarez Álvarez  from the University of Malaga (Spain) has been awarded a VM grant for 1500 € (17 Oct.-31 Oct. 2022)
  • Camilla Stephens from the University of Malaga (Spain) has been awarded a VM grant for 750 € (17 Oct.-31 Oct. 2022)
  • Jane Grove from the University of Nottingham (UK) has been awarded a VM grant for 750 € (14 oct-31 oct. 2022)
  • Daniel Di Zeo from the University of Malaga (Spain) has been awarded a VM grant for 1500 € (01 Jul.2022-15 Oct.2022) (E-COST-GRANT-CA17112-7bf207db)
  • Laura Moran from the University Complutense of Madrid (Spain) has been awarded a VM grant for 1500 €.